Event-Driven Stocks

Beta Bionics, Inc.

BBNXNasdaq

Healthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 4 good● 4 warningdetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23
Revenue$100.3M$65.1M$12.0M
Operating income−$71.7M−$45.3M−$35.9M
Net income−$73.2M−$54.8M−$44.1M
Total assets$328.7M$149.6M$110.0M
Total liabilities$41.1M$73.6M$51.4M
Equity$287.6M−$245.4M−$203.1M
EPS (diluted)$-1.81$-8.60$-8.31
Shares out.43.3M6.7M5.3M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−71.5%
Net margin
−73.0%
Return on equity
−25.5%
Return on assets
−22.3%
Return on capital (ROCE)
−24.1%
Liabilities / assets
12.5%
Debt / equity
0.14×
Book value / share
$6.63
Revenue growth (YoY)
53.9%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
6.94safe
Accruals / assets
−6.8%clean
Beneish M-Score
-1.73elevated
Piotroski F-Score
4/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
60
/ 100
Profitability 0Growth 100Catalyst 33Earnings quality 67Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →

Signs

● 4 warning● 4 good
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Negative operating cash flow
  • Beneish M-Score elevated — earnings-manipulation screen flag
  • Revenue is growing year-over-year
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)
  • Altman Z″ in the safe zone

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Insider transactions

SEC Form 4 · most recent
7 acquisitions5 disposalsnet +389,943 shares · last 12
InsiderDateTypeSharesPrice
Michel Gerard JDirectorMay 21, 2026Grant16,965$0.00
Jones ChristyDirectorMay 21, 2026Sell1,998$9.95
Palasis MariaDirectorMay 21, 2026Grant16,965$0.00
Dearen Danny L.DirectorMay 21, 2026Grant16,965$0.00
Carney SeanDirectorMay 21, 2026Grant16,965$0.00
Lezack AdamDirectorMay 21, 2026Sell1,000$9.95
Hopman MarkOfficer — Chief Commercial OfficerDec 2, 2025Sell856$29.34
Russell Steven JonOfficer — Chief Medical OfficerDec 2, 2025Sell1,025$29.34
Hopman MarkOfficer — Chief Commercial OfficerMar 4, 2026Sell353$11.57
Hopman MarkOfficer — Chief Commercial OfficerFeb 27, 2026Grant109,105$0.00
Russell Steven JonOfficer — Chief Medical OfficerFeb 27, 2026Grant109,105$0.00
Mensinger MikeOfficer — Chief Product OfficerFeb 27, 2026Grant109,105$0.00

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 20265.7M9.1-8.2%
Apr 30, 20266.2M5.2-13.2%
Apr 15, 20267.1M6.6-6.1%
Mar 31, 20267.6M6.5+8.5%
Mar 13, 20267.0M6.3+24.5%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.